Jim Simons Biotechnology

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
GLSI Greenwich Life Sciences, Inc.	$134M	$254,000 0.0% of portfolio	22,700	Q4 2024 Reduced 30.15%
ATNM Actinium Pharmaceuticals, Inc.	$45.6M	$239,000 0.0% of portfolio	190,400	Q4 2024 Added 49.92%
FHTX Foghorn Therapeutics Inc.	$147M	$225,000 0.0% of portfolio	47,736	Q4 2024 Added 89.16%
AIKI A Ikido Pharma Inc.	$20.8M	$214,000 0.0% of portfolio	56,326	Q4 2024 Added 20.03%
GHRS Gh Research PLC	$575M	$212,000 0.0% of portfolio	30,300	Q4 2024 Reduced 0.33%
EQ Equillium, Inc.	$14.1M	$206,000 0.0% of portfolio	261,400	Q4 2024 Reduced 18.61%
RGLS Regulus Therapeutics Inc.	$25.3M	$185,000 0.0% of portfolio	117,100	Q4 2024 Added 20.47%
ENLV Enlivex Therapeutics Ltd.	$18.8M	$184,000 0.0% of portfolio	158,992	Q4 2024 Added 112.59%
PROK Prokidney Corp Ord Shs Cl A(Cy	$56M	$177,000 0.0% of portfolio	105,200	Q4 2024 Added 127.71%
BOLT Bolt Biotherapeutics, Inc.	$15.8M	$166,000 0.0% of portfolio	302,039	Q4 2024 Added 2.72%
SPRB Spruce Biosciences, Inc.	$7.07M	$166,000 0.0% of portfolio	405,900	Q4 2024 Reduced 33.43%
PDSB Pds Biotechnology Corp	$35.9M	$163,000 0.0% of portfolio	100,000	Q4 2024 Added 331.03%
CNTB Connect Biopharma Holdings LTD	$37.4M	$161,000 0.0% of portfolio	134,697	Q4 2024 Reduced 23.25%
ALVR Allovir, Inc.	$913M	$159,000 0.0% of portfolio	379,563	Q4 2024 Reduced 51.14%
ARQT Arcutis Biotherapeutics, Inc.	$947M	$154,000 0.0% of portfolio	11,099	Q4 2024 Reduced 94.22%
OCUP Ocuphire Pharma, Inc.	$20.2M	$142,000 0.0% of portfolio	145,509	Q4 2024 Added 106.08%
ENTX Entera Bio Ltd.	$50.4M	$128,000 0.0% of portfolio	61,800	Q4 2024 Added 0.98%
DRTS Alpha Tau Medical Ltd.	$177M	$127,000 0.0% of portfolio	41,000	Q4 2024 Added 188.73%
ATHA Athira Pharma, Inc.	$11.3M	$122,000 0.0% of portfolio	207,300	Q4 2024 Reduced 54.22%
VACC Vaccitech PLC	$127M	$119,000 0.0% of portfolio	35,100	Q4 2024 Added 25.81%
AVTE Aerovate Therapeutics, Inc.	$61.9M	$118,000 0.0% of portfolio	44,600	Q4 2024 Added 149.16%
IOBT Io Biotech, Inc.	$34.6M	$109,000 0.0% of portfolio	118,800	Q4 2024 Added 22.47%
OVID Ovid Therapeutics Inc.	$25.4M	$100,000 0.0% of portfolio	107,700	Q4 2024 Added 142.02%
RNXT Renovo Rx, Inc.	$9.07M	$92,000 0.0% of portfolio	64,900	Q4 2024 New
RLMD Relmada Therapeutics, Inc.	$8.58M	$85,000 0.0% of portfolio	164,513	Q4 2024 Added 535.48%
HOWL Werewolf Therapeutics, Inc.	$30.1M	$84,000 0.0% of portfolio	56,900	Q4 2024 Reduced 62.61%
SNSE Sensei Biotherapeutics, Inc.	$15.7M	$78,000 0.0% of portfolio	156,800	Q4 2024 Reduced 27.26%
PMCB Pharma Cyte Biotech, Inc.	$27.4M	$76,000 0.0% of portfolio	49,300	Q4 2024 Reduced 0.8%
ARMP Armata Pharmaceuticals, Inc.	$57.1M	$74,000 0.0% of portfolio	40,291	Q4 2024 Reduced 13.35%
CGTX Cognition Therapeutics Inc	$9.54M	$68,000 0.0% of portfolio	91,100	Q4 2024 Added 2.71%
INKT Mi Nk Therapeutics, Inc.	$305M	$68,000 0.0% of portfolio	101,707	Q4 2024 Reduced 4.67%
TNGX Tango Therapeutics, Inc.	$129M	$66,000 0.0% of portfolio	21,500	Q4 2024 New
IMAB I Mab	$69.8M	$54,000 0.0% of portfolio	63,800	Q3 2023 Reduced 74.1%
AIM Aim Immuno Tech Inc.	$5.77M	$52,000 0.0% of portfolio	260,479	Q4 2024 Added 7.1%
VIRX Viracta Therapeutics, Inc.	$751K	$45,000 0.0% of portfolio	286,395	Q4 2024 Added 16.71%
DYAI Dyadic International Inc	$38.9M	$43,000 0.0% of portfolio	24,900	Q4 2024 Added 8.26%
CLGN Coll Plant Biotechnologies LTD	$28.3M	$38,000 0.0% of portfolio	10,600	Q4 2024 New
LXRX Lexicon Pharmaceuticals, Inc.	$108M	$37,000 0.0% of portfolio	51,141	Q4 2024 New
ANIX Anixa Biosciences Inc	$91.1M	$36,000 0.0% of portfolio	14,573	Q4 2024 Added 36.54%
STTK Shattuck Labs, Inc.	$44.9M	$34,000 0.0% of portfolio	28,100	Q4 2024 Reduced 88.79%
SILO Silo Pharma, Inc.	$3.92M	$33,000 0.0% of portfolio	37,500	Q4 2024 Reduced 83.48%
TCRX T Scan Therapeutics, Inc.	$25.6M	$32,000 0.0% of portfolio	10,600	Q4 2024 Reduced 85.68%
IPA Immuno Precise Antibodies Ltd.	$9.69M	$31,000 0.0% of portfolio	78,200	Q4 2024 Added 29.68%
BTAI Bio Xcel Therapeutics, Inc.	$59.4M	$28,000 0.0% of portfolio	77,900	Q4 2024 Reduced 40.02%
INDP Indaptus Therapeutics, Inc.	$4.87M	$23,000 0.0% of portfolio	27,700	Q4 2024 Added 2.21%
BYSI Beyond Spring Inc.	$56.1M	$18,000 0.0% of portfolio	11,600	Q4 2024 Reduced 0.85%
OMGA Omega Therapeutics, Inc.	$957K	$13,000 0.0% of portfolio	17,820	Q4 2024 Reduced 96.25%
ACXP Acurx Pharmaceuticals, Inc.	$4.74M	$11,000 0.0% of portfolio	14,674	Q4 2024 New
ONVO Organovo Holdings, Inc.	$21M	$11,000 0.0% of portfolio	31,630	Q4 2024 Reduced 28.16%
GLYC Glycomimetics Inc	$11.5M	$10,000 0.0% of portfolio	41,153	Q4 2024 Reduced 94.73%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account